Associate Professor of Clinical Medicine, Houston Methodist Endocrinology; Director, Houston Methodist Bone Health Initiative
Houston Methodist Hospital
Houston, Texas
Laila S. Tabatabai, M.D., is the Director of the Houston Methodist Bone Health Initiative (BHI) and Associate Professor of Clinical Medicine in the Division of Endocrinology. She received her medical degree, with distinction in research, at Albany Medical College in Albany, New York and her postdoctoral training included a fellowship in endocrinology at Johns Hopkins Hospital in Baltimore. Dr. Tabatabai is an expert in the field of anabolic agents for treatment of fragility fractures in high-risk osteoporosis patients. Dr. Tabatabai is considered a regional and national expert in rare bone diseases. She has the largest cohort of X-linked hypophosphatemic rickets patients in the southwest region and is the lead investigator on the multi-center, longitudinal disease monitoring program of XLH patients on burosumab at Houston Methodist.
Disclosure information not submitted.
Understanding CRYSVITA® (burosumab-twza), an FGF23Targeted Therapy sponsored by Kyowa Kirin
Friday, February 21, 2025
9:00 AM – 9:45 AM East Coast USA Time